产品
编 号：F751390
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2342597-93-5
产品详情
生物活性：
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer.
体内研究：
Ociperlimab (BGB-A1217; 3 和 10 mg/kg; 腹腔注射; CT26 WT 荷瘤人源化 TIGIT 敲入小鼠和 MC38 荷瘤人源化 TIGIT 敲入小鼠) 以 Fc 依赖性方式产生抗肿瘤功效。Animal Model:CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice
Dosage:3 and 10 mg/kg
Administration:Intraperitoneal injection
Result:Inhibited tumor growth compared to the single agent treatment groups.
体外研究：
Ociperlimab (BGB-A1217; 0-10 μg/mL) 增强增强巨细胞病毒特异性 T 细胞分泌的 IFN-γ。Ociperlimab (1-1000 ng/mL) 以 Fc 依赖性方式激活自然杀伤细胞和单核细胞。Ociperlimab 在体外通过 Fc 依赖性内吞作用从 T 细胞表面去除 TIGIT。
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer.
体内研究：
Ociperlimab (BGB-A1217; 3 和 10 mg/kg; 腹腔注射; CT26 WT 荷瘤人源化 TIGIT 敲入小鼠和 MC38 荷瘤人源化 TIGIT 敲入小鼠) 以 Fc 依赖性方式产生抗肿瘤功效。Animal Model:CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice
Dosage:3 and 10 mg/kg
Administration:Intraperitoneal injection
Result:Inhibited tumor growth compared to the single agent treatment groups.
体外研究：
Ociperlimab (BGB-A1217; 0-10 μg/mL) 增强增强巨细胞病毒特异性 T 细胞分泌的 IFN-γ。Ociperlimab (1-1000 ng/mL) 以 Fc 依赖性方式激活自然杀伤细胞和单核细胞。Ociperlimab 在体外通过 Fc 依赖性内吞作用从 T 细胞表面去除 TIGIT。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备